

► PŘEHLEDOVÉ ČLÁNKY

INHIBÍTOŘY KOMPLEMENTU EKULIZUMAB A RAVULIZUMAB V LIEČBE GENERALIZOVANEJ MYASTÉNIE GRAVIS (GMG)

ema.europa.eu/en/documents/product-information/soliris-epar-product-information_en.pdf.

5. European Medicines Agency. Ultomiris® (ravulizumab) Summary of Product Characteristics. Dostupné na: https://www.ema.europa.eu/sk/documents/product-information/ultomiris-epar-product-information_sk.pdf.

6. Fakhouri F, Schwotzer N, Golshayan D, Frémeaux-Bacchi V. The Rational Use of Complement Inhibitors in Kidney Diseases. *Kidney Int Rep.* 2022;7(6):1165-1178. doi: 10.1016/j.ekir.2022.02.021.

7. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. *N Engl J Med.* 2006;355(12):1233-43. doi: 10.1056/NEJMoa061648.

8. Howard Jr JF. Myasthenia gravis: the role of complement at the neuromuscular junction. *Ann NY Acad Sci.* 2018;1412(1):113-128. doi: 10.1111/nyas.13522.

9. Howard Jr JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. *Lancet Neurol.* 2017;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1

10. Mantegazza R, O'Brien FL, Yountz M, Howard Jr JF, REGAIN Study Group. Consistent improvement with eculizumab across muscle groups in myasthenia gravis. *Ann Clin Transl Neurol.* 2020;7(8):1327-1339. doi: 10.1002/acn3.51121

11. Mantegazza R, Wolfe GI, Muppidi S, et al. Post-interven-

tion Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension. *Neurology.* 2021;96(4):e610-e618. doi: 10.1212/WNL.00000000000011207.

12. Meisel A, Annane D, Vu T, et al. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. *J Neurol.* 2023 Aug;270(8):3862-3875. doi: 10.1007/s00415-023-11699-x

13. Menon D, Barnett C, Bril V. Novel Treatments in Myasthenia Gravis. *Front Neurol.* 2020;11:538. doi: 10.3389/fneur.2020.00538.

14. Muppidi S, Utsugisawa K, Benatar M, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. *Muscle Nerve.* 2019;60(1):14-24. doi: 10.1002/mus.26447.

15. Narayanaswami P, Sanders DB, Wolfe GI, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. *Neurology.* 2021;96(3):114-122. doi: 10.1212/WNL.00000000000011124.

16. Pittock SJ, Berthele A, Fujihara K. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. *N Engl J Med.* 2019;381(7):614-625. doi: 10.1056/NEJMoa1900866.

17. Špalek P. Myasténia gravis. *Cesk Slov Neurol N.* 2008;71/104(1):7-24.

18. Špalek P. Intravenózný imunoglobulín v liečbe myasténie gravis. *Neurológia.* 2018;13:53-58.

19. Vanoli F, Mantegazza R. Current drug treatment of myasthenia gravis. *Curr Opin Neurol.* 2023;36(5):410-415. doi: 10.1097/WCO.0000000000001196.

20. Voháňka S. Farmakoterapie myasthenia gravis. *Neurol. praxi.* 2010;11(2):95-99.

21. Vissing J, Jacob S, Fujita KP, et al, REGAIN Study Group. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. *J Neurology.* 2020;267(7):1991-2001. doi: 10.1007/s00415-020-09770-y.

22. Vu T, Meisel A, Mantegazza R, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. *Neurol Ther.* 2023;12(5):1435-1438. doi: 10.1007/s40120-023-00514-4.

23. Vu T, Ortiz S, Katsuno M, et al. Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. *J Neurol.* 2023;270(6):3129-3137. doi: 10.1007/s00415-023-11617-1.

24. Vu T, Wiendl H, Katsuno M, et al. Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence. *Neuropsychiatr Dis Treat.* 2023;19:2639-2655. doi: 10.2147/NDT.S374694.

25. Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. *Pediatr Nephrol.* 2019;34(11):2261-2277. doi: 10.1007/s00467-018-4091-3.

26. Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. *N Engl J Med.* 2016;375(6):511-22. doi: 10.1056/NEJMoa1602489.

ON-LINE KURZ

Zaostřeno na syndrom Dravetové

OBSAH KURZU

- Co víme o syndromu Dravetové u dospělých? – prof. MUDr. Petr Marusič, Ph.D.
- Na co ještě myslet u dětí? – MUDr. Martin Kudr, Ph.D.
- Cesta k diagnóze – dialog s genetikem – MUDr. Katalin Štěrbová
- Cesta k diagnóze – dialog s genetikem – MUDr. Jana Zárubová
- Cesta k diagnóze – dialog s genetikem – MUDr. Markéta Vlčková, Ph.D.
- Mechanismus účinku a protizáchvatová aktivita fenfluraminu – MUDr. Ondřej Horák, doc. MUDr. Irena Doležalová, Ph.D.

ODBOBNÝ GARANT:

doc. MUDr. Irena Doležalová, Ph.D.

POŘADATEL:

Společnost SOLEN, s. r. o.,
ve spolupráci s I. neurologickou klinikou LF MU
a FN u sv. Anny

Registrace
ZDARMA

TERMÍN

květen 2024 až duben 2025

dostupný na
online.solen.cz



ZLATÝ
PARTNER



Inspired by patients.
Driven by science.

